Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

218 Applying Pharmacogenomics in Therapeutics
23. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R, et al. Further evidence
of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J
Med Genet B Neuropsychiatr Genet 2004;15:36–40.
24. Taylor MJ, Sen J, Bhagwagar Z. Antidepressant response and the serotonin transporter
gene-linked polymorphic region. Biol Psychiatry 2010;68:536–543.
25. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings
in major depressive disorder. Mol Psychiatry 2010;15:473–500.
26. Dettling M, Cascorbi I, Opgen-Rhein C, Schaub R. Clozapine-induced agranulocytosis
in schizophrenic Caucasians: Confirming clues for associations with human leukocyte
class I and II antigens. Pharmacogenomics J 2007;7(5):325–332.
27. Athanasiou MC, Dettling MC, Cascorbi I, Mosyagin I, Salisbury BA, Pierz KA, et al.
Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with
clozapine-induced agranulocytosis. J Clin Psychiatry 2011;72(4):458–463.
28. Ostrousky O, Meged S, Loewenthal R, Valevski A, Weizman A, Carp H, et al.
NQO2 gene is associated with clozapine-induced agranulocytosis. Tissue Antigens
2003;62(6):483–491.
29. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side
effects and agranulocytosis. Curr Psychiatry Rep 2011;13:156–165.
30. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1:
A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum Mutat
2004; 23(6):540–545.
31. Zai CC, Romano-Silva MA, Hwang R, Zai GC, Deluca V, Muller DJ, et al. Genetic
study of eight AKT1 gene polymorphisms and their interaction with DRD2 gene polymorphisms
in tardive dyskinesia. Schizophr Res 2008;106(2):248–252.
32. Tsai HT, North KE, West SL, et al. The DRD3 rs6280 polymorphism and prevalence
of tardive dyskinesia: a meta-analysis. Am J Med Genet B Neuropsychiatr Genet
2010;153B(1):57–66.
33. Mannisto PT, Ulnianen I, Lundstrom K, et al. Characteristics of catechol-Omethyltransferase
(COMT) and properties of selective COMT inhibitors. Prog Drug
Res 1992;39:291–350.
34. Hori H, Ohmori O, Shinkai T, Kojima J, Okano C, Suzuki T, et al. Manganese superoxide
dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia.
J Neuropsychopharmacol 2000;23(2):170–177.
35. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, et al. Combined
analysis of 635 patients confirms an age-related association of the serotonin 2A receptor
gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J
Neuropsychopharmacol 2005;8(3):411–425.
36. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk
of tardive dyskinesia in schizophrenia: A meta-analysis. Pharmacogenet Genomics
2005;15(3):151–158.
37. Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and antipsychotics:
New findings from animal model and pharmacogenomic studies. Schizophr
Res Treat 2011;2011:459284, pp. 1–16.
38. De Luca V, Mueller DJ, de Bartolomeis A, Kennedy J. Association of the HTR2C gene
and antipsychotic induced weight gain: A meta-analysis. Int J Neuropsychopharmacol
2007;10:697–704.
39. Zai CC, De Luca V, Hwang RW, et al. Meta-analysis of two dopamine D2 receptor
gene polymorphisms with tardive dyskinesia in schizophrenic patients. Mol Psychiatry
2007;12:794–795.
40. Shamy MCF, Zai C, Basile VS, Kennedy J, Muller DJ, Masellis M. Ethical and policy considerations
in the application of pharmacogenomics testing for tardive dyskinesia: Case
study of the dopamine D3 receptor. Curr Pharmacogenomics Pers Med 2011;9:94–101.